Protalix signs supply deal with Brazilian govt

by The Associated Press

Shares of Protalix BioTherapeutics Inc. jumped in premarket trading Wednesday after the drug developer announced a deal that requires the Brazilian government to buy at least $280 million of the company's Gaucher disease treatment.

The Israeli company said an arm of the Brazilian Ministry of Health has committed to buying at least $40 million of the drug annually during the seven-year agreement for Uplyso, which is marketed as Elelyso in the United States and Israel.

During the agreement, Protalix will transfer the technology needed for the Brazilian government to build at its own expense a factory to make a sustainable supply of Uplyso. Protalix doesn't have to complete the final stage of its technology transfer until the government has made at least $280 million in Uplyso purchases.

Protalix worked with ., the world's second-largest drugmaker, to develop Elelyso, and it will have to pay Pfizer a maximum of about $12.5 million from its annual profits generated in Brazil during the agreement. Pfizer returned its commercialization rights to the drug in Brazil to Protalix.

is a caused by deficiency of an important enzyme. The condition can cause liver and neurological problems.

The and Israeli regulators approved Elelyso last year, and Brazilian regulators approved it in March.

U.S.-traded shares of Protalix jumped 9.3 percent, or 47 cents, to $5.54 in premarket trading about two hours ahead of the market opening.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Pfizer will buy NextWave Pharma for up to $700M

Oct 22, 2012

(AP)—Pfizer said Monday it will buy NextWave Pharmaceuticals Inc., a company that makes a liquid attention deficit hyperactivity disorder drug, in a deal worth as much as $700 million.

Elan enters $1B royalty deal with Theravance

May 13, 2013

Irish drugmaker Elan Corp. PLC plans to pay $1 billion for the right to future royalties from four respiratory treatments being developed by Theravance Inc. and GlaxoSmithKline.

Recommended for you

WHO: Millions of Ebola vaccine doses ready in 2015

19 hours ago

The World Health Organization says millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines will start being tested in March.

Added benefit of vedolizumab is not proven

Oct 23, 2014

Vedolizumab (trade name Entyvio) has been approved since May 2014 for patients with moderately to severely active Crohn disease or ulcerative colitis. In an early benefit assessment pursuant to the Act on the Reform of the ...

Seaweed menace may yield new medicines

Oct 22, 2014

An invasive seaweed clogging up British coasts could be a blessing in disguise. University of Greenwich scientists have won a cash award to turn it into valuable compounds which can lead to new, life-saving drugs.

User comments